pioglitazone has been researched along with Demyelinating Diseases in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardo, A | 1 |
| Giammarco, ML | 1 |
| De Nuccio, C | 1 |
| Ajmone-Cat, MA | 1 |
| Visentin, S | 1 |
| De Simone, R | 1 |
| Minghetti, L | 1 |
| Duvanel, CB | 1 |
| Honegger, P | 1 |
| Pershadsingh, H | 1 |
| Feinstein, D | 1 |
| Matthieu, JM | 1 |
2 other studies available for pioglitazone and Demyelinating Diseases
| Article | Year |
|---|---|
Docosahexaenoic acid promotes oligodendrocyte differentiation via PPAR-γ signalling and prevents tumor necrosis factor-α-dependent maturational arrest.
Topics: Animals; Cell Differentiation; Cells, Cultured; Demyelinating Diseases; Docosahexaenoic Acids; Fatty | 2017 |
Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Astrocytes; Cells, Cultured; Complement Syste | 2003 |